63,500 Shares in AtriCure Inc. (ATRC) Acquired by Lockheed Martin Investment Management Co.

Lockheed Martin Investment Management Co. purchased a new position in AtriCure Inc. (NASDAQ:ATRC) during the first quarter, Holdings Channel reports. The fund purchased 63,500 shares of the medical device company’s stock, valued at approximately $1,216,000.

Other institutional investors have also bought and sold shares of the company. Parametric Portfolio Associates LLC boosted its position in AtriCure by 11.2% in the first quarter. Parametric Portfolio Associates LLC now owns 34,622 shares of the medical device company’s stock worth $663,000 after buying an additional 3,488 shares during the period. Swiss National Bank boosted its position in AtriCure by 7.0% in the first quarter. Swiss National Bank now owns 54,700 shares of the medical device company’s stock worth $1,048,000 after buying an additional 3,600 shares during the period. Bank of New York Mellon Corp boosted its position in AtriCure by 24.2% in the first quarter. Bank of New York Mellon Corp now owns 179,586 shares of the medical device company’s stock worth $3,439,000 after buying an additional 35,013 shares during the period. Wells Fargo & Company MN boosted its position in AtriCure by 131.9% in the first quarter. Wells Fargo & Company MN now owns 112,006 shares of the medical device company’s stock worth $2,145,000 after buying an additional 63,711 shares during the period. Finally, Rockefeller Financial Services Inc. boosted its position in AtriCure by 185.0% in the first quarter. Rockefeller Financial Services Inc. now owns 11,766 shares of the medical device company’s stock worth $225,000 after buying an additional 7,637 shares during the period. 79.30% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Shares of AtriCure Inc. (NASDAQ:ATRC) traded up 1.51% during midday trading on Friday, reaching $21.50. The company had a trading volume of 224,838 shares. The company’s market capitalization is $729.84 million. AtriCure Inc. has a one year low of $13.45 and a one year high of $23.95. The company has a 50 day moving average of $20.47 and a 200 day moving average of $18.64.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, May 4th. The medical device company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.01. AtriCure had a negative return on equity of 19.84% and a negative net margin of 23.78%. The business had revenue of $41.30 million for the quarter, compared to the consensus estimate of $40.25 million. During the same quarter last year, the business posted ($0.31) earnings per share. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. Analysts predict that AtriCure Inc. will post ($0.95) EPS for the current fiscal year.

WARNING: “63,500 Shares in AtriCure Inc. (ATRC) Acquired by Lockheed Martin Investment Management Co.” was originally published by Mideast Time and is the property of of Mideast Time. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.mideasttime.com/63500-shares-in-atricure-inc-atrc-acquired-by-lockheed-martin-investment-management-co/1709119.html.

A number of equities analysts have recently commented on the company. TheStreet raised AtriCure from a “d+” rating to a “c-” rating in a report on Monday. Zacks Investment Research lowered AtriCure from a “buy” rating to a “hold” rating in a research report on Wednesday, May 10th. Needham & Company LLC restated a “buy” rating and set a $25.00 price objective (up previously from $23.00) on shares of AtriCure in a research report on Friday, May 5th. Canaccord Genuity restated a “buy” rating and set a $22.00 price objective on shares of AtriCure in a research report on Monday, April 17th. Finally, Northland Securities restated a “buy” rating and set a $24.00 price objective on shares of AtriCure in a research report on Monday, March 20th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $22.13.

In other news, SVP Andrew L. Lux sold 20,000 shares of AtriCure stock in a transaction dated Friday, March 17th. The stock was sold at an average price of $18.85, for a total value of $377,000.00. Following the transaction, the senior vice president now owns 85,589 shares in the company, valued at $1,613,352.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $21.44, for a total value of $214,400.00. Following the completion of the transaction, the director now owns 24,162 shares in the company, valued at approximately $518,033.28. The disclosure for this sale can be found here. Company insiders own 10.00% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

12 Month Chart for NASDAQ:ATRC

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.